Combination with IGF1R, PI3K inhibitors

Slides:

Advertisements

Similar presentations

Targeting the IGF Pathway in Pediatric Sarcomas-Lessons Learned and Questions Raised Lee J. Helman, M.D. Scientific Director for Clinical Research,Center.

Advertisements

TSC and LAM: Current Treatment Options and Clinical Trials

Preclinical Models for Developing Therapy for Pediatric Solid Tumors Preclinical Models for Developing Therapy for Pediatric Solid Tumors uses and limitations.

Metabolic Syndrome: Focused on AMPK as Molecular Target for Metabolic Syndrome Bayu Lestari.

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma by Thomas E. Witzig,

Systemic treatment of renal cell cancer: A comprehensive review

TARGETING HSP90 IN IM-RESISTANT GIST:

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

PI3K inhibition does not Effect the BH3 Profile of SW620 Cells

Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells Dianren Xia1, Lauren.

Targeting signal transduction

by Rogelio Zamilpa, and Merry L. Lindsey

Metastatic HER2+ Breast Cancer: Resistance

Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma Fred C. Lam, Michael B. Yaffe Cancer.

LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT Jacob M. Kaufman,

PI3K Pathway Inhibitors

Overall Program Goals. Overall Program Goals Current Approaches.

تحليل الحساسية Sensitive Analysis.

Figure 1: Assessment of eribulin activity in twenty-five cell lines

IRS-1: Auditing the effectiveness of mTOR inhibitors

Leptin and insulin signalling pathways in the Arc.

Figure 4 Possible combination therapies CDK4/6 inhibitors

Treating mRCC After Initial Antiangiogenic Therapy:

Treatment of HR+ Breast Cancer: A Clinical Update

Figure 3 Defects in the T cell receptor signalling pathway

Yanxin Pei, Robert J. Wechsler-Reya Cancer Cell

A Flt3L Encounter: mTOR Signaling in Dendritic Cells

LKB1 Kinase: Master and Commander of Metabolism and Polarity

Alexander L. Fogel, BS, Sharleen Hill, MD, Joyce M.C. Teng, MD, PhD

Figure 1 mTOR complex biology

Schematic representation of main EGFR-TKIs resistance mechanisms.

Doubling Down on mTOR Inhibition: Harnessing ZEBRA for Insights

Targeted Therapies in Melanoma: Translational Research at Its Finest

Review AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism CELL METABOLISM : JANUARY 2005 · VOL.

Volume 29, Issue 3, Pages (March 2016)

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Maria M. Mihaylova, David M. Sabatini, Ömer H. Yilmaz Cell Stem Cell

EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?

Apoptosis-targeted therapies for cancer

Volume 22, Issue 6, Pages (December 2012)

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills Cancer Cell

Nat. Rev. Urol. doi: /nrurol

The PI3K Pathway in Human Disease

Keiran S.M. Smalley Journal of Investigative Dermatology

FGFR Signaling as a Target for Lung Cancer Therapy

IRS-1: Auditing the effectiveness of mTOR inhibitors

HIV Drug to Aid Melanoma Therapies?

The LKB1-AMPK Pathway—Friend or Foe in Cancer?

High-throughput combination drug screening to nominate potent drug combinations. High-throughput combination drug screening to nominate potent drug combinations.

Figure 1 The mTOR signalling pathway

Youry Kim, Jenny L. Anderson, Sharon R. Lewin Cell Host & Microbe

NOTCH and PI3K-AKT Pathways Intertwined

Targeted Therapies for Hepatocellular Carcinoma

LKB1 and Src: Antagonistic Regulators of Tumor Growth and Metastasis

Model of the BET and MEK inhibitor combination therapy to treat melanoma with NRAS mutation and immune therapy resistance Model of the BET and MEK inhibitor.

Tumor Metabolism: MAGE-A Proteins Help TRIM Turn Over AMPK

Apoptosis-targeted therapies for cancer

Volume 6, Issue 2, Pages (January 2014)

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD

Smoothing Out Drug Resistance

Volume 8, Issue 5, Pages (September 2014)

BC Basics 2017.

Dysregulation of the mTOR Pathway Secondary to Mutations or a Hostile Microenvironment Contributes to Cancer and Poor Wound Healing Richard A.F. Clark,

Simplified BRAF signaling network.

Quantitative PTEN protein expression is associated with pertuzumab sensitivity in vitro and trastuzumab resistance in vivo. Quantitative PTEN protein expression.

High nuclear β-catenin levels confer resistance to AKT inhibition and coordinates with increased nuclear FOXO3a to promote metastasis in colon cancer.

Connections between insulin/insulin-like growth factor 1 signaling and metabolic pathways in tumor cells. Connections between insulin/insulin-like growth.

HER2 and PI3K-targeted therapies result in FOXO3a-mediated feedback upregulation of HER3 and IGF1R and provide an escape from PI3K pathway inhibition.

Giulia Tarantola, Humanitas University

Presentation transcript:

Combination with IGF1R, PI3K inhibitors 1. mTOR activated tumors Optimize rapalogs Combination with IGF1R, PI3K inhibitors Personalized reversal of loops ? 2. mTOR-addicted tumors ATP-competitive inhibitors Targeted therapies ? 1st line therapy Intrinsic resistance 4EBP1/ eIF4E expression Combination with eIF4E inhibitors coexisting oncogenic mutation Combination therapy K-Ras mutations Everolimus sensitivity High sensitivity 3. Magnitude of everolimus efficacy in LKB1-AMPK or PI3K-AKT activated pathway ? In order to differenciate mTor and PI3K inhibitors